0001562180-23-008222.txt : 20231207
0001562180-23-008222.hdr.sgml : 20231207
20231207210312
ACCESSION NUMBER: 0001562180-23-008222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231205
FILED AS OF DATE: 20231207
DATE AS OF CHANGE: 20231207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Liu Ye
CENTRAL INDEX KEY: 0001840407
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 231473789
MAIL ADDRESS:
STREET 1: ROOM 502-I, WANT WANT PLAZA
STREET 2: NO. 211 SHIMEN YI ROAD
CITY: SHANGHAI
STATE: F4
ZIP: 200041
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2023-12-05
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001840407
Liu Ye
56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD
JING'AN DISTRICT
SHANGHAI
200041
true
false
false
false
false
Common Stock, $0.001 par value
2023-12-05
4
S
false
733758.00
19.91
D
2276963.00
I
Ocumension Therapeutics
Common Stock, $0.001 par value
2023-12-06
4
S
false
266242.00
18.41
D
2010721.00
I
Ocumension Therapeutics
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $20.38. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.49. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Ron Honig, Attorney-in-Fact
2023-12-07